Imagine making a three-hour round trip every day for standard insulin, statins, or a preventative puff of an asthma inhaler. Imagine the burden of structuring your day, job, and life around a taxing commute through unpredictable Massachusetts traffic, just to receive a single dose of critical medication. Fortunately, most essential medications are as close as the local pharmacy. But for thousands of people across the Commonwealth, these exhausting daily commutes are a mandatory part of accessing methadone, the gold-standard treatment for Opioid Use Disorder (OUD).

“I’d have to leave the house at 6:00 am. I wouldn’t get back till like 9:00 am and so if I had a job to do or any other thing I could do, I couldn’t do it. Like seven days a week. It was horrible.” – Alex* 

My team heard this and many similar stories from patients seeking methadone treatment as part of an ongoing evaluation this past year.

Compared to insulin, or an asthma inhaler, methadone is significantly harder to access. Federal regulations restrict its dispensing to specialty clinics known as Opioid Treatment Programs, or OTPs. In 2024, a report commissioned by the Massachusetts Department of Public Health found 55 brick-and-mortar OTPs in the state, largely concentrated around major cities. This creates significant obstacles for people like Alex, who live in rural, low-access regions, for whom recovery requires hours on the road.

However, that reality is beginning to change.

Through an investment from the MA Bureau of Substance Addiction Services (BSAS), mobile medication units (MMUs) were launched in high-need locations. There are now four MMUs operating across Massachusetts, two of which are in rural locations. For patients like Alex, the impact was immediate. Alex shared that it now takes them just fifteen minutes to get to the MMU. 

The Institute for Community Health (ICH) is currently collaborating with BSAS to evaluate this model of expanding methadone access across the Commonwealth. Our team has talked to patients and staff at MMUs to understand the experiences and impacts of dosing, operating, and implementing a mobile model.

MMUs assume the travel burden for their patients on a near-daily basis. In general, units travel early each morning from their “home” OTP to their approved secondary site, operating for two to four hours from a community partner’s back parking lot. MMUs are tied to their “home” OTP’s license, meaning staff load and unload the unit at the OTP each day.

While the primary goal of this model is to improve access to methadone, we learned that the MMU model yields unexpected and positive outcomes beyond convenience. Patients and staff described an environment that feels quicker, calmer, more dignified, and more private. The MMU allows for a more intimate setting, fostering a stronger rapport between patients and staff. The combination of enhanced access and improved environment has been deeply impactful on patients’ medication continuity and lives. Staff shared in their interviews that they have observed increased medication adherence and powerful life transformations in short amounts of time.

“…when a patient misses medicating for a day we refer to it as an AWOL. So this particular patient, he had a very hard time getting to a brick and mortar. He was constantly AWOLing. And as soon as our mobile unit opened, he medicated for like 30 days straight without missing a day.” – Staff member 

We also learned that the impacts of these MMUs extend beyond the patient. Staff shared that the mobile model has sparked curiosity within OTPs, aided in recruiting new patients to their panels, furthered staff development, and allowed for differentiation from other OTPs in their area.

ICH’s next steps in this evaluation are to better understand the reach of the MMUs through a quantitative analysis using electronic medical record (EMR) data. With this data we also plan to quantitatively assess how medication continuity has been impacted by the introduction of MMUs.

These findings lead us to a compelling lesson: when people can’t get in the door to treatment—maybe because it’s too far, too taxing—find a way to move the door. Establishing a traditional brick-and-mortar OTP in rural and underserved regions is complicated by funding shortages, community resistance, and local political pressure. This reality means that we need to continue looking for alternative ways to fill the gap. There is a vital need for innovative treatment models—with MMUs being just one example—to ensure the people who need methadone can access it. By relocating the “front door” of treatment, we can not only encourage initiating care, but also ensure recovery for rural-located patients like Alex remains viable and sustainable long-term. 

Without evaluation, this program’s impacts may have gone unnoticed, and we are grateful to our partners and study participants for allowing us to tell this story. Evaluation is a valuable tool for increasing access to essential health care. By documenting outcomes and implementation lessons that other practitioners and funders can learn from, evaluators like ICH shine a light on the need for deepened investment in innovative care models.

*Note: Alex is a pseudonym used to protect patient privacy and confidentiality.